Brief: Lee's Pharmaceutical Updates On Trial Of Adapalene-Clindamycin Combination Gel In China
22/06/2020 10:12
June 22 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* LEE'S PHARMACEUTICAL- UNIT SUCCESSFULLY COMPLETED ITS
PIVOTAL
PHASE III TRIAL OF ADAPALENE-CLINDAMYCIN COMBINATION GEL IN
CHINA
* LEE'S PHARMACEUTICAL- NEW DRUG APPLICATION SUBMISSION AND
MARKETING APPROVAL EXPECTED IN SECOND HALF OF 2020 AND IN 2021,
RESPECTIVELY
Source text for Eikon: ID:nHKSbxps5Q
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lee's Pharmaceutical Holdings
See all newsHong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales
Brief: Lee's Pharmaceutical Expects H1 Net Profit Of HK$85 Million-HK$95 Million
Brief: Lee's Pharmaceutical Says Investigational New Drug Application For ADC Project ZK2401 Accepted By NMPA
Brief: Ashlins Pharmaceuticals And Lee's Pharm Announce Exclusive License And Supply Agreement Valued At Up To $31 Million
Brief: Lee's Pharmaceutical Says Entered Licensing Agreement With Ashlins Ocular Pharmaceuticals